Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs ; volume:19 ; number:5 ; day:31 ; month:7 ; year:2024 ; pages:797-809 ; date:9.2024
Targeted oncology ; 19, Heft 5 (31.7.2024), 797-809, 9.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-024-01081-w
- URN
-
urn:nbn:de:101:1-2411262127012.386577089159
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Michaeli, Daniel
- Michaeli, Christoph T.
- Albers, Sebastian
- Michaeli, Julia
- SpringerLink (Online service)
Ähnliche Objekte (12)
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
Post-FDA Approval Results of Epithelium-Off, Full-Fluence, Dresden Protocol Corneal Collagen Crosslinking in the USA
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
Post-FDA Approval Results of Epithelium-Off, Full-Fluence, Dresden Protocol Corneal Collagen Crosslinking in the USA
FDA efficiency for approval process of COVID-19 therapeutics
Analysis of FDA's Accelerated Approval Program Performance December 1992–December 2021
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA
FDA
FDA
FDA
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective